Atavistik Bio announced results from its Series B financing round, raising $120 million to support the advancement of selective allosteric small molecule therapeutics for the treatment of HHT and MPNs respectfully.

The therapy options include its oral allosteric AKT1-selective inhibitor for HHT and the JAK2 V617F mutant-selective inhibitor program for MPNs, both of which were discovered using Atavistik Bio’s proprietary AMPS platform.¹

Atavistik Bio’s proprietary AMPS platform is a highly integrated discovery engine combining both proprietary computational and experimental techniques to accelerate the process of unlocking functional cryptic pockets across a wide range of target classes.⁴ The platform leverages its insights from allosteric chemical starting points to enable the design of small molecules against challenging targets.

The JAK2 V617F mutation is the most common driver mutation in patients living with MPNs, affecting an estimated 95% of patients with polycythemia vera (PV), 60% of patients with essential thrombocythemia (ET) and 55% of patients with myelofibrosis (MF).² Selectively targeting the JAK2 V617F mutation holds the potential to reduce mutant allele burden, modify disease progression, and significantly enhance treatment outcomes for patients suffering from MPNs.

Selectively inhibiting AKT1, the primary AKT isoform and driver of abnormal endothelial growth implicated in HHT, offers a novel and potentially disease-modifying therapeutic approach for this difficult disease.³ Atavistik Bio’s oral allosteric inhibitor selectively inhibits AKT1, overcoming the shortcomings of pan-AKT inhibitors while simultaneously offering improved therapeutic potential and tolerability.³

“We’ve been continually impressed by the exceptional quality of the compounds discovered from Atavistik Bio’s proprietary AMPS™ platform and by the team’s ability to consistently execute against critical milestones,” said Atavistik Board Chair John A. Josey, PhD. “Atavistik Bio’s HHT and MPN programs would represent enormous advancements in the treatment of these respective diseases. We look forward to seeing Atavistik Bio move these programs into the clinic and bring them closer to patients in need.”

What are the details of the financing round?

Nextech Invest and The Column Group lead the financing, including participation from Atavistik Bio’s existing investor Lux Capital, along with a new investor Regeneron Ventures.¹

Atavistik Bio plans to use the proceeds from its Series B financing to advance its oral allosteric AKT1-selective inhibitor for HHT and its JAK2 V617F mutant-selective inhibitor program for MPNs through clinical proof of concept.¹

“We’re thrilled to announce our Series B financing, and grateful for the support of both our existing and new investors. With this capital, we are well-positioned to advance both our HHT and MPN programs through key clinical proof-of-concept milestones, with the HHT program expected to enter the clinic in the first half of 2026,” said Bryan Stuart, chief executive officer at Atavistik Bio. “Our precision allostery approach holds tremendous potential to deliver best-in-class therapeutics with superior efficacy and tolerability profiles. Our team is working with tremendous passion and momentum to translate that promise into meaningful outcomes for patients.”

Sources

1. Atavistik Bio Raises $120 Million Series B Financing to Advance the Development of Selective Allosteric Small Molecule Therapeutics for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT) and Myeloproliferative Neoplasms (MPNs) Atavistik Bio December 18, 2025 https://atavistikbio.com/companynews/atavistik-bio-raises-120-million-series-b-financing-to-advance-the-development-of-selective-allosteric-small-molecule-therapeutics-for-the-treatment-of-hereditary-hemorrhagic-telangiectasia-hht-and/
2. Atavistik Bio to Present Discovery of JAK2 V617F Mutant-Selective Allosteric Inhibitors for the Treatment of Myeloproliferative Neoplasms (MPNs) at ASH 2025 Atavistik Bio December 4, 2025 https://atavistikbio.com/companynews/atavistik-bio-to-present-discovery-of-jak2-v617f-mutant-selective-allosteric-inhibitors-for-the-treatment-of-myeloproliferative-neoplasms-mpns-at-ash-2025/
3. Robust Pipeline of Precision Therapeutics Atavistik Bio Accessed December 19, 2025, https://atavistikbio.com/pipeline/
4. Atavistik Bio Announces Research Collaboration with Pfizer to Accelerate Discovery of Novel Precision Allosteric Therapeutics Atavistik Bio January 2, 2025 https://atavistikbio.com/companynews/atavistik-bio-announces-research-collaboration-with-pfizer-to-accelerate-discovery-of-novel-precision-allosteric-therapeutics/#:~:text=Atavistik%20Bio's%20proprietary%20AMPS%E2%84%A2%20platform%20is%20a%20highly%20integrated,medicines%20across%20any%20therapeutic%20area